GlobeNewswire Inc | Oct 26, 2020 08:00AM EDT

October 26, 2020

Dupixent (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

-- First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older -- New late-breaking data show additional improvements in disease severity and extent, as well as normalized gene expression associated with type 2 inflammation -- Data from this trial further supports well-established safety profile of Dupixent -- Results presented for the first time at virtual ACG 2020 and UEG Week 2020 -- Dupixent received FDA Breakthrough Therapy designation for patients 12 years and older with EoE

PARIS and TARRYTOWN, N.Y. October 26, 2020 Additional positive results were announced from Part A of a pivotal Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) in patients 12 years and older with eosinophilic esophagitis (EoE). As previously reported, the trial met both of its co-primary and all key secondary endpoints. New late-breaking data showing additional improvements in disease severity and extent at the microscopic level, as well as normalization of gene expression pattern associated with type 2 inflammation, were presented at the virtual American College of Gastroenterology (ACG) Annual Scientific Meeting and the United European Gastroenterology (UEG) Week Virtual 2020.

There are currently no FDA-approved medicines for EoE, a chronic and progressive inflammatory disease that damages the esophagus and prevents it from working properly. Over time, excessive type 2 inflammation may cause scarring and narrowing of the esophagus, making it difficult to swallow. EoE can affect a patients ability to eat and cause food to become stuck after being swallowed (food impaction), which can lead to a medical emergency.

Previously announced results showed Dupixent improved symptomatic, structural and histologic measures of EoE. The use of Dupixent to treat EoE is investigational and has not been fully evaluated by any regulatory authority.

The results from this trial show dupilumab significantly improved both patients ability to swallow as well as structural abnormalities in the esophagus, by targeting type 2 inflammation to help reverse tissue damage and scarring that usually worsens over time, said Evan S. Dellon, M.D., M.P.H., Professor of Gastroenterology and Hepatology at the University of North Carolina School of Medicine and principal investigator of the trial. These results also demonstrate that eosinophilic esophagitis is a disease caused by factors beyond just the presence of elevated eosinophils. Dupilumab, which targets the activity of the cytokines IL-4 and IL-13 that drive type 2 inflammation, was able to show significant improvements in a broad range of clinical, anatomic, cellular and molecular measures.

Part A of the randomized, double-blind, placebo-controlled trial enrolled 81 patients aged 12 years and older with EoE, who were treated with Dupixent 300 mg weekly over a 24-week treatment period or placebo.

New results presented at virtual ACG 2020 and UEG Week 2020 showed patients treated with Dupixent experienced:

-- Rapid improvement in ability and comfort of swallowing: patients reported significant improvement on the Dysphagia Symptom Questionnaire (DSQ) as early as 4 weeks and continued to improve through 24 weeks (p<0.05 and p<0.001, respectively). -- Reduced esophageal eosinophil count below the diagnostic disease threshold: 64% of patients treated with Dupixent achieved <15 eosinophils/high-power field (eos/hpf) compared to 8% for placebo at 24 weeks (p<0.001). Peak esophageal eosinophil count was reduced by 71% with Dupixent compared to 3% with placebo from baseline (p<0.001). -- Reduced severity and extent of the disease at the microscopic level: the grade and stage scores that measure esophageal tissue changes associated with the disease were reduced by 0.761 and 0.753 with Dupixent compared to a 0.001 and 0.012 reduction for placebo at 24 weeks; the EoE Histology Scoring System (EoE-HSS) grade and stage scores measure changes in eight cellular and tissue features on four-point scales, respectively (p<0.001 for all values). -- Normalized gene expression in esophageal tissue: gene expression patterns associated with type 2 inflammation and EoE were reduced by 1.97-fold and 2.66-fold, compared to a 0.32-fold and 0.16-fold reduction with placebo, respectively, as measured by the Normalized Enrichment Score (NES) at 24 weeks from baseline. The NES evaluated a panel of genes associated with type 2 inflammation or EoE (p<0.001 for all values). The changes observed with Dupixent demonstrate a shift in gene expression pattern from one that resembles EoE disease to a pattern that resembles healthy controls.

The trial demonstrated similar safety results to the well-established safety profile of Dupixent in its approved indications. For the 24-week treatment period, overall rates of adverse events were 86% for Dupixent and 82% for placebo. Adverse events that were more commonly observed with Dupixent included injection site reactions (n=15 for Dupixent, n=12 for placebo) and upper respiratory tract infections (n=11 for Dupixent, n=6 for placebo). There was one treatment discontinuation in the Dupixent group due to joint pain.

In September, the FDA granted Breakthrough Therapy designation to Dupixent for the treatment of patients 12 years and older with EoE. Breakthrough Therapy designation is designed to expedite the development and review of drugs in the U.S. that target serious or life-threatening conditions. Drugs qualifying for this designation must show preliminary clinical evidence that it may demonstrate a substantial improvement on clinically significant endpoints over available therapies, or over placebo if there are no available therapies. In 2017, Dupixent also was granted Orphan Drug designation for the potential treatment of EoE. This is given to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. and in which no adequate medicines have been developed and approved.

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis.

About the Dupixent eosinophilic esophagitis trial

The Phase 3, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in adolescents and adults with eosinophilic esophagitis. Part A of the trial enrolled 81 patients (42 treated with Dupixent and 39 with placebo) aged 12 years and older with EoE, as determined by histological and patient-reported measures. The co-primary endpoints assessed the change from baseline in the DSQ, a patient-reported measure of difficulty swallowing, and the proportion of patients achieving peak esophageal intraepithelial eosinophil count of 6 eos/hpf, a measure of esophageal inflammation, at 24 weeks. Key secondary endpoints of the trial assessed histopathologic measures of the severity and extent of tissue scarring in the esophagus, as measured by the EoE-HSS grade and stage scores, and the proportion of patients achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf at 24 weeks. Other secondary endpoints of the trial assessed NES for the relative change from baseline to week 24 in the EoE diagnostic panel and type 2 inflammation transcriptome signatures. In total, 85% of these patients suffered from at least one concurrent atopic condition such as allergic rhinitis, food allergy and asthma. Patients received weekly subcutaneous injections of Dupixent 300 mg or placebo for the 24-week treatment period.

The EoE trial is ongoing, with additional patients enrolling in Part B as well as patients continuing in a 28-week extended active treatment period (Part C) after completing either Part A or Part B. Part B of the trial is evaluating an additional Dupixent dosing regimen.

About Dupixent

Dupixent is approved for adolescents and adults with moderate-to-severe atopic dermatitis, asthma and/or in adults with CRSwNP in a number of countries around the world, including the European Union and Japan, as well as the U.S. where Dupixent is also approved for children with moderate-to-severe atopic dermatitis. Dupixent is currently approved in more than 60 countries, and more than 190,000 patients have been treated globally.

Dupilumab development program

To date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including EoE (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2). These potential uses are investigational, and the safety and efficacy of dupilumab in these conditions have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton

Sanofi Media Relations Contact Sally BainTel.: +1 (781) 264-1091 Sanofi Investor Relations Contacts NorthSally.Bain@sanofi.com America Felix Lauscher Fara Berkowitz Suzanne Greco



Sanofi IR main line: Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com https://www.sanofi.com/en/investors/contact

Regeneron Media Relations Contact Regeneron Investor Relations ContactSharon Chen Vesna TosicTel: +1 (914) 847-1546 Tel: +1 (914) 847-5443Sharon.Chen@regeneron.com Vesna.Tosic@regeneron.com

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates regarding the marketing and other potentialof the product, or regarding potential future revenues from the product.Forward-looking statements are generally identified by the words ?expects?,?anticipates?, ?believes?, ?intends?, ?estimates?, ?plans? and similarexpressions. Although Sanofi?s management believes that the expectationsreflected in such forward-looking statements are reasonable, investors arecautioned that forward-looking information and statements are subject tovarious risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of Sanofi, that could cause actual results anddevelopments to differ materially from those expressed in, or implied orprojected by, the forward-looking information and statements. These risks anduncertainties include among other things, unexpected regulatory actions ordelays, or government regulation generally, that could affect the availabilityor commercial potential of the product, the fact that product may not becommercially successful, the uncertainties inherent in research anddevelopment, including future clinical data and analysis of existing clinicaldata relating to the product, including post marketing, unexpected safety,quality or manufacturing issues, competition in general, risks associated withintellectual property and any related future litigation and the ultimateoutcome of such litigation, and volatile economic and market conditions, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2019. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Regeneron Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks anduncertainties relating to future events and the future performance of RegeneronPharmaceuticals, Inc. (?Regeneron? or the ?Company?), and actual events orresults may differ materially from these forward-looking statements. Words suchas ?anticipate,? ?expect,? ?intend,? ?plan,? ?believe,? ?seek,? ?estimate,?variations of such words, and similar expressions are intended to identify suchforward-looking statements, although not all forward-looking statements containthese identifying words. These statements concern, and these risks anduncertainties include, among others, the impact of SARS-CoV-2 (the virus thathas caused the COVID-19 pandemic) on Regeneron?s business and its employees,collaborators, and suppliers and other third parties on which Regeneron relies,Regeneron?s and its collaborators? ability to continue to conduct research andclinical programs, Regeneron?s ability to manage its supply chain, net productsales of products marketed by Regeneron and/or its collaborators (collectively,?Regeneron?s Products?), and the global economy; the nature, timing, andpossible success and therapeutic applications of Regeneron?s Products andRegeneron?s product candidates and research and clinical programs now underwayor planned, including without limitation Dupixent^ (dupilumab) in patients 12years and older with eosinophilic esophagitis; uncertainty of market acceptanceand commercial success of Regeneron?s Products and product candidates and theimpact of studies (whether conducted by Regeneron or others and whethermandated or voluntary), including the study discussed in this press release, onthe commercial success of Regeneron's Products (such as Dupixent) and productcandidates; the likelihood, timing, and scope of possible regulatory approvaland commercial launch of Regeneron?s product candidates and new indications forRegeneron?s Products, such as Dupixent for the treatment of eosinophilicesophagitis, pediatric asthma, pediatric atopic dermatitis, chronic obstructivepulmonary disease, bullous pemphigoid, prurigo nodularis, chronic spontaneousurticaria, food and environmental allergies, and other potential indications;safety issues resulting from the administration of Regeneron?s Products (suchas Dupixent) and product candidates in patients, including seriouscomplications or side effects in connection with the use of Regeneron?sProducts and product candidates in clinical trials; determinations byregulatory and administrative governmental authorities which may delay orrestrict Regeneron?s ability to continue to develop or commercializeRegeneron?s Products and product candidates; ongoing regulatory obligations andoversight impacting Regeneron?s Products, research and clinical programs, andbusiness, including those relating to patient privacy; the availability andextent of reimbursement of Regeneron?s Products from third-party payers,including private payer healthcare and insurance programs, health maintenanceorganizations, pharmacy benefit management companies, and government programssuch as Medicare and Medicaid; coverage and reimbursement determinations bysuch payers and new policies and procedures adopted by such payers; competingdrugs and product candidates that may be superior to, or more cost effectivethan, Regeneron?s Products and product candidates; the extent to which theresults from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead toadvancement of product candidates to clinical trials, therapeutic applications,or regulatory approval; the ability of Regeneron to manufacture and managesupply chains for multiple products and product candidates; the ability ofRegeneron?s collaborators, suppliers, or other third parties (as applicable) toperform manufacturing, filling, finishing, packaging, labeling, distribution,and other steps related to Regeneron?s Products and product candidates;unanticipated expenses; the costs of developing, producing, and sellingproducts; the ability of Regeneron to meet any of its financial projections orguidance and changes to the assumptions underlying those projections orguidance; the potential for any license or collaboration agreement, includingRegeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical IndustriesLtd. (or their respective affiliated companies, as applicable), to be cancelledor terminated; and risks associated with intellectual property of other partiesand pending or future litigation relating thereto (including without limitationthe patent litigation and other related proceedings relating to EYLEA(aflibercept) Injection, Dupixent, and Praluent^ (alirocumab)), otherlitigation and other proceedings and government investigations relating to theCompany and/or its operations, the ultimate outcome of any such proceedings andinvestigations, and the impact any of the foregoing may have on Regeneron'sbusiness, prospects, operating results, and financial condition. A morecomplete description of these and other material risks can be found inRegeneron?s filings with the U.S. Securities and Exchange Commission, includingits Form 10-K for the year ended December 31, 2019 and its Form 10-Q for thequarterly period ended June 30, 2020. Any forward-looking statements are madebased on management?s current beliefs and judgment, and the reader is cautionednot to rely on any forward-looking statements made by Regeneron. Regeneron doesnot undertake any obligation to update publicly any forward-looking statement,including without limitation any financial projection or guidance, whether as aresult of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social mediaoutlets to publish important information about the Company, includinginformation that may be deemed material to investors. Financial and otherinformation about Regeneron is routinely posted and is accessible onRegeneron's media and investor relations website ( http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron).





Attachment

-- Press Release